Pathoquest
Paris, FR· latest recorded location
PATHOQUEST is named on 6 US grants and 8 published applications in this corpus. Its most frequent classification is C12Q (Measuring or testing processes involving enzymes, nucleic acids or microorganisms).
- Granted patents
- 6
- Published applications
- 8
- Inventors
- 15
- Granted in 2026 so far
- 0
- Most recent grant
- 3 Sep 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 2 |
| 2020 | 0 | 0 |
| 2021 | 0 | 3 |
| 2022 | 2 | 0 |
| 2023 | 1 | 0 |
| 2024 | 1 | 1 |
By publication year.
Technology areas
Share of 14 documents
Recent patents
- Anellovirus genome quantification as a biomarker of immune suppression3 Sep 2024US 12,077,829 B2
- Method for discriminating between live and dead microbes in a sample3 Jan 2023US 11,542,563 B2
- Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages20 Dec 2022US 11,530,452 B2
- Modulation of accessibility of host nucleic acids to nucleic acid digesting enzymes in acellular biological fluids5 Apr 2022US 11,293,049 B2
- Anellovirus genome quantification as a biomarker of immune suppression4 Dec 2018US 10,144,975 B2
- Anellovirus genome quantification as a biomarker of immune suppression7 Nov 2024US 2024/0368713 A1
- Method for discriminating between live and dead microbes in a sample22 Jul 2021US 2021/0222261 A1
- Method for discriminating between live and dead microbes in a sample25 Mar 2021US 2021/0087642 A1
- Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages4 Feb 2021US 2021/0032705 A1
- Anellovirus genome quantification as a biomarker of immune suppression21 Mar 2019US 2019/0085418 A1
Most cited
By later US patents
None of its patents has been cited by a later US patent yet.